POINT Biopharma Global, Inc.
(NASDAQ CM: PNT)
Rigrodsky Law, P.A. is investigating POINT Biopharma Global, Inc. (“POINT”) regarding possible breaches of fiduciary duties and other violations of law related to POINT’s agreement to be acquired by Eli Lilly and Company. Under the terms of the agreement, POINT shareholders will receive $12.50 per share in cash.